Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL)

Condition:   Lymphoma Intervention:   Drug: Pembrolizumab Sponsor:   Abramson Cancer Center of the University of Pennsylvania Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials